Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subjects

NCT07204639 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: RAP103 400mg single dose
DRUG: RAP103 200mg BID
DRUG: Placebo for RAP400
DRUG: Placebo for RAP200mg

Sponsor

Clarent Biopharma, Inc.

Collaborators

[object Object]
[object Object]
[object Object]